The endocrinologist says fear, judgment and misinformation still shape how people see GLP-1 drugs, and asks patients to learn before deciding.
Recap by typeshit. Post by @drsalaswhalen on Instagram.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
A TriNetX analysis presented at ASCO Breakthrough found 0.20% vs 0.43% five-year cancer rates. Lead author Sarina Ailawadi says prospective studies are still needed.
One UT San Antonio study found about 16% lower incidence in high-risk women with obesity. Discussant Rayjean Hung flagged biases that could inflate the effect.
Loading…